Tepp RIA LLC Invests $1.07 Million in Astrazeneca Plc $AZN

Tepp RIA LLC acquired a new position in Astrazeneca Plc (NYSE:AZN) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 14,002 shares of the company’s stock, valued at approximately $1,074,000. Astrazeneca makes up approximately 1.2% of Tepp RIA LLC’s investment portfolio, making the stock its 11th biggest position.

A number of other institutional investors have also recently bought and sold shares of AZN. Rakuten Investment Management Inc. bought a new position in Astrazeneca in the third quarter valued at approximately $31,000. FSA Wealth Management LLC lifted its stake in Astrazeneca by 376.0% during the second quarter. FSA Wealth Management LLC now owns 476 shares of the company’s stock worth $33,000 after purchasing an additional 376 shares during the last quarter. VSM Wealth Advisory LLC bought a new stake in Astrazeneca during the second quarter worth $33,000. E Fund Management Hong Kong Co. Ltd. boosted its holdings in shares of Astrazeneca by 144.0% in the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 466 shares of the company’s stock valued at $36,000 after purchasing an additional 275 shares in the last quarter. Finally, Abound Wealth Management increased its stake in shares of Astrazeneca by 1,767.9% in the 3rd quarter. Abound Wealth Management now owns 523 shares of the company’s stock valued at $40,000 after purchasing an additional 495 shares during the last quarter. Institutional investors own 20.35% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on AZN. TD Cowen reissued a “buy” rating on shares of Astrazeneca in a report on Tuesday, December 9th. HSBC reaffirmed a “buy” rating and issued a $108.00 price objective on shares of Astrazeneca in a research note on Wednesday, December 10th. Barclays reiterated an “overweight” rating on shares of Astrazeneca in a research report on Tuesday, January 6th. Guggenheim reissued a “buy” rating on shares of Astrazeneca in a report on Wednesday, December 3rd. Finally, Weiss Ratings began coverage on shares of Astrazeneca in a research note on Wednesday. They issued a “buy (b)” rating on the stock. Nine research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $95.75.

Astrazeneca Price Performance

NYSE AZN opened at $190.20 on Friday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 0.72 and a current ratio of 0.94. Astrazeneca Plc has a twelve month low of $122.48 and a twelve month high of $212.71. The firm has a market cap of $294.98 billion, a P/E ratio of 29.04, a PEG ratio of 1.45 and a beta of 0.32.

Astrazeneca Dividend Announcement

The company also recently declared a dividend, which will be paid on Monday, March 23rd. Stockholders of record on Friday, February 20th will be paid a dividend of $1.595 per share. This represents a dividend yield of 156.0%. The ex-dividend date of this dividend is Friday, February 20th. Astrazeneca’s dividend payout ratio (DPR) is presently 66.26%.

Astrazeneca Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.